Suraksha starts FY27 with margin expansion and a wider map

Suraksha Diagnostic Limited began FY27 with a quarter that combined growth, profitability, and visible operating leverage. For Q1 FY27, consolidated revenue from operations was INR 876.45 million, while total income was INR 887.33 million. EBITDA rose to INR 315.30 million, translating into a 36.0% margin, and profit after tax came in at INR 128.45 million with a 14.7% PAT margin. Year-on-year, revenue grew 20.7%, EBITDA grew 27.9%, and PAT grew 40.0%.

The numbers were supported by higher patient throughput and a richer test mix. The company served 0.38 million patients and performed 2.10 million tests during the quarter. Revenue per patient was INR 2,321 and EBITDA per patient was INR 835. Management stated that the improvement in margins was driven primarily by volume-led operating leverage as revenues scaled while major fixed costs remained largely stable. It also said there was no price increase, and that realization uplift was a mix effect.

Q1 FY27 snapshot: growth plus operating leverage

Suraksha’s profitability improved at both the consolidated level and at the centre cohort level. Mature centres (older than two years) delivered a 40.9% EBITDA margin in Q1 FY27, and centres under two years old turned profitable at 6.5% EBITDA margin, improving from negative 5.5% in Q4 FY26. Management described this as the ramp-up it had been building towards.

B2C continued to be the dominant engine, contributing 91% of Q1 FY27 revenue. On the call, management reiterated that it does not pursue deep discounting in collection centres and sees B2C as structurally healthier for realizations. It also acknowledged that B2B carries margin pressure, but said volumes help offset this.

Accounting presentation also matters in diagnostics due to leases. The company provided an Ind AS vs IGAAp bridge for Q1 FY27, noting that Ind AS 116 capitalises leases and replaces rental expense with depreciation and finance cost. Under the IGAAp view in the presentation, EBITDA was shown at INR 248.2 million versus INR 315.3 million under Ind AS, while PAT under IGAAp was shown at INR 145.0 million.

Expansion is widening beyond West Bengal

Suraksha’s network expansion remained active through Q1 and into early Q2. The company ended Q1 FY27 with 72 centres, up from 68 in Q4 FY26 and 58 in Q1 FY26. During Q1 it commissioned one hub and three spoke centres. It then added two hubs and three spokes in July and August.

The most notable strategic development was the move beyond West Bengal. Management said it commissioned its first hub centre in Jharkhand (Dhanbad) and a hub in Tripura would follow shortly. The FY27 expansion plan table in the presentation lists launched and upcoming centres across Greater Kolkata, Rest of Bengal, Jharkhand, Tripura, Assam and Bihar.

The current revenue base remains West Bengal heavy. The presentation states West Bengal accounted for 95.5% of FY26 revenue from operations, and Q1 geography split shows 67% from Greater Kolkata and 29% from the rest of Bengal, with Assam at 3% and Bihar at 1%.

Suraksha reiterated the logic of its concentric hub-and-spoke approach. In the call, management explained that it typically opens a hub and then adds spokes around it, while sample collection centres sit further out. All 214 sample collection centres are franchisee-owned, and management said a high-performing collection location can later be upgraded to a spoke.

Genomics is small but scaling fast

Suraksha Genomics continues to be positioned as a future pillar. Q1 FY27 genomics revenue was INR 13.7 million, up 136% year-on-year, and the presentation shows five consecutive quarters of sequential growth (Q1 FY26: 5.8 million; Q2 FY26: 6.8 million; Q3 FY26: 8.5 million; Q4 FY26: 11.5 million; Q1 FY27: 13.7 million).

Management described the current genomics mix as 80% B2C and 20% B2B, while indicating B2B could rise over time. It also shared that genomics margins were around 15% to 20% at present. The strategic focus areas mentioned included prenatal diagnostics, inherited disease testing, pharmacogenomics, and oncology molecular panels.

In the call, management added two specific examples of technology-led work: it had introduced a blood test for Alzheimer disease with good doctor feedback, and it had started an AI project for early detection of Alzheimer disease from plain brain MRI with support from CSIR.

On capex requirements for genomics, management said the major investment is already done and it does not expect additional major capex for the next two to three years. It also disclosed that around INR 22 crore had been spent over three years on genomics capacity.

What management guided for FY27 and beyond

The company provided several forward-looking datapoints on the call, largely focused on margins, capex, and network growth.

First, on profitability, management said it believes FY27 overall EBITDA margin will not go below 34%. It also suggested that margins could be higher by FY28-FY29.

Second, on capex, management guided FY27 capex at around INR 70 to 80 crore. It also provided indicative capex per centre: a hub typically costs INR 10 to 10.5 crore, and a spoke costs INR 1.5 to 2 crore.

Third, on expansion milestones, management said it is on track to open 100 centres by FY28. It clarified centre openings planned for FY27 in the Q and A, indicating that after the centres already opened, it plans to add more hubs and spokes within the year, and the presentation’s FY27 table shows 4 hubs and 7 spokes as upcoming.

Finally, on centre ramp-up, management stated that a spoke reaches centre-level break-even in about three to four months, while head-office level break-even takes about eight to nine months.

Takeaways

Suraksha’s Q1 FY27 performance showed a blend of strong year-on-year growth and margin expansion, supported by higher throughput, richer mix, and operating leverage. The improvement in under-two-year centres to positive EBITDA at the cohort level is an important operational signal because it suggests the expansion engine is starting to feed, rather than dilute, profitability.

The strategy remains consistent: deepen density in the core West Bengal market, while methodically stepping into adjacent eastern states using the same hub-and-spoke playbook. Genomics is still small in absolute terms, but the company is highlighting it with measurable traction, disclosed investment levels, and a clear intent to leverage existing infrastructure without heavy incremental capex.